港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

銀諾醫藥-B

21.600

-0.500-2.26%

成交量：28.36萬

成交額：610.13萬

市值：98.71億

市盈率：-51.89

高：22.800

開：22.140

低：20.800

收：22.100

52周最高：74.000

52周最低：20.800

股本：4.57億

香港流通股本：4.20億

量比：0.76

換手率：0.07%

股息：- -

股息率：- -

每股收益(LYR):-0.416

淨資產收益率：-23.27%

總資產收益率：-11.61%

市淨率：12.74

市盈率(LYR):-51.89

市銷率: 154.15

資料載入中...

總覽公司新聞資訊公告

港股異動 | 銀諾醫藥-B(02591)盤中跌超5% 預期年度產生虧損約3.414億元年內研發開支增加

銀諾醫藥-B(02591)發盈警預期2025年產生虧損約3.414億元

智通财经网

銀諾醫藥-B預計全年虧損擴大研發投入激增1.03億元

銀諾醫藥-B（02591）：預計2025年度虧損擴大至約3.41億元

銀諾醫藥－Ｂ(02591)股價上升5.126%，現價港幣$23.38

阿斯达克财经

銀諾醫藥-B(02591)擬實施H股全流通計劃

IPO「黑函」頻現港交所「密交」擴容箭在弦上

21世纪经济报道

銀諾醫藥-B(02591.HK)3月23日舉行董事會會議考慮及批准全年業績

銀諾醫藥新獸藥推進6000L產能工藝變更申報

兽药信息资讯

銀諾醫藥-B03月05日獲主力加倉53.6萬元

浦東創新藥上市首年即進駐上海50+醫療機構，創新落地「不減速」！浦東全鏈條支撐顯成效

銀諾醫藥-B（02591）2月股份變動月報：股本保持穩定

銀諾醫藥-B盤中異動股價大跌5.43%報23.000港元

世界肥胖日｜告別"周拋"針！銀諾醫藥積極探索"每月一針"減重新方案

銀諾醫藥-B盤中異動早盤股價大跌5.40%

銀諾醫藥-B02月25日主力淨流入70.2萬元散户資金拋售

銀諾醫藥全速「UP」，錨定創新與供應雙目標，助力上海生物醫藥產業升級

銀諾醫藥-B02月10日主力淨流入318.7萬元散户資金拋售

國產寵物減肥降糖藥進入臨床試驗，給狗和貓注射GLP-1藥物靠譜嗎？

銀諾醫藥-B(02591)：楊東妍獲委任為聯席公司秘書

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02591/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"銀諾醫藥-B","latestPrice":21.6,"timestamp":1773994127289,"preClose":22.1,"halted":0,"volume":283600,"delay":0,"changeRate":-0.02262443438914027,"floatShares":420285370,"shares":457000000,"eps":-0.416279,"marketStatus":"休市中","change":-0.5,"latestTime":"03-20 16:08:47","open":22.14,"high":22.8,"low":20.8,"amount":6101272,"amplitude":0.090498,"askPrice":21.6,"askSize":5600,"bidPrice":20.86,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-0.533,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":7,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":22.1,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":0.7628167192986008,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-11.61%","roe":"-23.27%","lyrEps":-0.416279,"volumeRatio":0.7628167192986008,"shares":457000000,"dividePrice":0,"high":22.8,"amplitude":0.090498,"preClose":22.1,"low":20.8,"week52Low":20.8,"pbRate":"12.74","psRate":"154.15","week52High":74,"institutionHeld":0,"latestPrice":21.6,"committee":-0.866667,"eps":-0.416279,"divideRate":0,"volume":283600,"delay":0,"ttmEps":-0.533,"open":22.14,"prevYearClose":30.64,"prevWeekClose":22.12,"prevMonthClose":27.8,"prevQuarterClose":30.64,"fiveDayClose":22.12,"twentyDayClose":27.7,"sixtyDayClose":30.94,"earningDate":1774195200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1770998400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-03-19","current":-40.525328,"percent":0.993103,"low":-137.156472,"twenty":-78.986763,"median":-59.815295,"eighty":-51.63405,"high":-39.965904,"avg":-66.870005,"sd":20.385249,"marketCap":10095707612},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-19","current":-40.08154,"twenty":-78.986763,"median":-59.815295,"eighty":-51.63405,"marketCap":10095707612}],"updateTime":1774041827808},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620201133","title":"港股異動 | 銀諾醫藥-B(02591)盤中跌超5% 預期年度產生虧損約3.414億元 年內研發開支增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2620201133","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620201133?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 11:48","pubTimestamp":1773978490,"startTime":"0","endTime":"0","summary":"消息面上，3月18日，银诺医药-B发布公告，尽管用于治疗2型糖尿病的依苏帕格鲁肽α于中国及澳门商业化上市后，集团于2025年度取得收益约人民币1.315亿元，集团预期本年度将取得亏损约人民币3.414亿元，而截至2024年12月31日止年度则取得亏损约人民币1.747亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","02591","BK4585","BK1161"],"gpt_icon":0},{"id":"2620970235","title":"銀諾醫藥-B(02591)發盈警 預期2025年產生虧損約3.414億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620970235","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620970235?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 16:37","pubTimestamp":1773823033,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B 公布，尽管用于治疗2型糖尿病的依苏帕格鲁肽α于中国及澳门商业化上市后，集团于2025年度取得收益约人民币1.315亿元，集团预期本年度将取得亏损约人民币3.414亿元，而截至2024年12月31日止年度则取得亏损约人民币1.747亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"银诺医药-B(02591)发盈警 预期2025年产生亏损约3.414亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1197852552","title":"銀諾醫藥-B預計全年虧損擴大 研發投入激增1.03億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197852552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197852552?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 16:37","pubTimestamp":1773823032,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司近日发布盈利预警公告，预计2023财年将录得显著亏损。公司指出，亏损主要源于研发费用的大幅增加，期内研发支出同比激增约1.03亿元人民币，同时销售及分销成本也有所上升。此次研发费用的大幅增长，反映了银诺医药在创新药管线上的持续投入。银诺医药-B的股价表现将在一定程度上取决于其核心产品能否取得突破性进展，以及公司现金储备能否支撑其研发计划至关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"1178999501","title":"銀諾醫藥-B（02591）：預計2025年度虧損擴大至約3.41億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178999501","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178999501?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 16:36","pubTimestamp":1773822994,"startTime":"0","endTime":"0","summary":"银诺医药-B3月18日晚间发布盈利预警称，预计2025年度将录得归属于母公司所有者的亏损约3.41亿元，而上年同期亏损约1.75亿元。期内，公司实现收入约1.32亿元，主要来自核心产品依苏帕格鲁肽α在中国及澳门上市后的商业化销售，上年同期收入为零。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"2620880092","title":"銀諾醫藥－Ｂ(02591)股價上升5.126%，現價港幣$23.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2620880092","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620880092?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 10:15","pubTimestamp":1773800100,"startTime":"0","endTime":"0","summary":"[上升股]银诺医药－Ｂ(02591) 股价在上午10:15比前收市价上升5.126%，现股价为港币$23.38。至目前为止，今日最高价为$23.38，而最低价为$22.0。总成交量为5.7万股，总成交金额为港币$129.277万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318601/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318601/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2620425636","title":"銀諾醫藥-B(02591)擬實施H股全流通計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425636","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620425636?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 18:38","pubTimestamp":1773743905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2026年3月17日，本公司已就建议将公司的全部境内未上市股份转换为本公司H股向中国证监会提交备案申请。于取得所有相关批准及 ╱ 或备案(包括中国证监会的备案通知及联交所的批准)及遵守所有适用法律、规则及法规后，该等境内非上市股份将转换为H股，而本公司将申请批准该等H股于联交所主板上市及买卖。根据本公司的组织章程细则，转换及上市毋须再召开股东会作批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2618070909","title":"IPO「黑函」頻現 港交所「密交」擴容箭在弦上","url":"https://stock-news.laohu8.com/highlight/detail?id=2618070909","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618070909?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 21:12","pubTimestamp":1773234772,"startTime":"0","endTime":"0","summary":"如今，为破解这一痛点，港交所正酝酿一场意义深远的上市制度改革。针对递表上市的“黑函”对于拟上市公司而言，在递交上市申请与通过聆讯之间，通常有数月的时间窗口。香港中小上市公司协会主席席春迎对此表示认同。它允许拟上市公司在通过聆讯前，无需公开披露其上市申请文件，从而获得一个宝贵的“静默期”。港交所此次考虑扩大保密申请范围，其底气正来自于自2018年以来一系列上市制度改革的成功，尤其是“科企专线”的积极反馈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311211842a46162c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311211842a46162c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["80388","02591","BK1131","BK1161"],"gpt_icon":0},{"id":"2618393390","title":"銀諾醫藥-B(02591.HK)3月23日舉行董事會會議考慮及批准全年業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2618393390","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618393390?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 17:07","pubTimestamp":1773133627,"startTime":"0","endTime":"0","summary":"格隆汇3月10日丨银诺医药-B(02591.HK)宣布，董事会会议将于2026年3月23日(星期一)举行，藉以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止年度之全年业绩及其刊发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260310/32057375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2618349692","title":"銀諾醫藥新獸藥推進6000L產能工藝變更申報","url":"https://stock-news.laohu8.com/highlight/detail?id=2618349692","media":"兽药信息资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618349692?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 09:11","pubTimestamp":1772932277,"startTime":"0","endTime":"0","summary":"公司项目推进在马年开工首日，公司宣布以“稳定供应、加速创新”为核心方向，全力配合核心产品依苏帕格鲁肽α纳入2025年国家医保目录的落地执行，并推进6000L产能工艺变更申报，以保障医疗机构的用药需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308091946a4572e92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308091946a4572e92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2617154781","title":"銀諾醫藥-B03月05日獲主力加倉53.6萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617154781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617154781?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 16:16","pubTimestamp":1772698566,"startTime":"0","endTime":"0","summary":"03月05日, 银诺医药-B股价涨2.06%，报收22.74元，成交金额938.7万元，换手率0.10%，振幅6.91%，量比0.89。银诺医药-B今日主力资金净流入53.6万元，连续3日净流入，上一交易日主力净流入179.8万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为57.14%，平均涨幅为2.37%。该股近5个交易日下跌17.37%，主力资金累计净流入346.0万元；近20日主力资金累计净流入1741.8万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162146a6a5cb16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305162146a6a5cb16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2616559227","title":"浦東創新藥上市首年即進駐上海50+醫療機構，創新落地「不減速」！浦東全鏈條支撐顯成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2616559227","media":"科Way","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616559227?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:22","pubTimestamp":1772616128,"startTime":"0","endTime":"0","summary":"浦东全链条赋能，创新落地“不减速”创新药如何在浦东实现高效研发、准入与应用？上市与应用在浦东“双提速”创新药械产品上市与应用的“提速”需要一套长效机制来支撑。据统计，在2025年，浦东新区共有8个国产1类新药、6个三类创新医疗器械获批上市。进入2026年，已有多款创新药械获批上市或正加速获批中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041826549542f713&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603041826549542f713&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02591","BK1161","06978"],"gpt_icon":0},{"id":"1186566011","title":"銀諾醫藥-B（02591）2月股份變動月報：股本保持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1186566011","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186566011?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 16:52","pubTimestamp":1772614332,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年3月4日发布截至2026年2月28日的证券变动月报表。报告显示，公司本月无新增股份发行或回购行为，股本结构保持稳定。公司注册资本合计为人民币456,819,349元，分为420,285,370股于香港联交所上市的H股，以及36,533,979股未上市股份。公司同时确认已符合香港联交所关于最低公众持股量的要求。公司声明将持续遵守香港联交所《上市规则》及相关法律规定。根据公告信息，本次月报由联席公司秘书杨东妍签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"2616559224","title":"銀諾醫藥-B盤中異動 股價大跌5.43%報23.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616559224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616559224?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:32","pubTimestamp":1772587950,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘09时32分，银诺医药-B股票出现异动，股价大幅跳水5.43%。截至发稿，该股报23.000港元/股，成交量4600股，换手率0.00%，振幅4.11%。资金方面，该股资金流入4700港元，流出7.0456万港元。银诺医药-B股票所在的生物技术行业中，整体跌幅为0.27%。其相关个股中，欧康维视生物-B、再鼎医药、东曜药业-B涨幅较大，振幅较大的相关个股有康诺亚-B、圣诺医药-B、泰格医药，振幅分别为8.15%、5.38%、5.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304093230a448d2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304093230a448d2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2616592225","title":"世界肥胖日｜告別\"周拋\"針！銀諾醫藥積極探索\"每月一針\"減重新方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2616592225","media":"银诺医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616592225?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:00","pubTimestamp":1772586022,"startTime":"0","endTime":"0","summary":"银诺医药积极响应，致力于通过科学研究为肥胖管理提供新的可能。公司在研药物依苏帕格鲁肽α的中国减重IIb期研究取得积极结果，验证了\"每2周一次\"给药方案的潜力；同时，在澳大利亚开展的II期多中心研究正在探索\"双周+月制剂\"的更长效给药方案。结果显示，经过18周治疗受试者平均体重较基线下降10%，平均腰围减少8.4cm。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304092335a69fa908&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304092335a69fa908&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2616380477","title":"銀諾醫藥-B盤中異動 早盤股價大跌5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616380477","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616380477?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 10:32","pubTimestamp":1772418725,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘10时32分，银诺医药-B股票出现波动，股价大幅下挫5.40%。截至发稿，该股报26.300港元/股，成交量10.32万股，换手率0.02%，振幅4.68%。银诺医药-B股票所在的生物技术行业中，整体跌幅为4.46%。其相关个股中，正大企业国际、派格生物医药-B、美因基因涨幅较大，振幅较大的相关个股有百奥赛图-B、MIRXES-B、荣昌生物，振幅分别为7.30%、7.19%、6.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302103205a440053a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302103205a440053a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2614036100","title":"銀諾醫藥-B02月25日主力淨流入70.2萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614036100","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614036100?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 16:16","pubTimestamp":1772007366,"startTime":"0","endTime":"0","summary":"02月25日, 银诺医药-B股价涨1.76%，报收27.72元，成交金额844.8万元，换手率0.07%，振幅2.86%，量比1.89。银诺医药-B今日主力资金净流入70.2万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.43%，主力资金累计净流入123.0万元；近20日主力资金累计净流出3378.7万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225162235a4c6685c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225162235a4c6685c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2613166117","title":"銀諾醫藥全速「UP」，錨定創新與供應雙目標，助力上海生物醫藥產業升級","url":"https://stock-news.laohu8.com/highlight/detail?id=2613166117","media":"劳动报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613166117?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 17:16","pubTimestamp":1771924565,"startTime":"0","endTime":"0","summary":"银诺医药正以产能升级助力上海生物医药产业规模提升，用实打实的供应保障交出开工答卷。姜帆表示，银诺医药将以马年开工为新起点，以“UP”的奋进姿态，持续聚焦创新药研发与商业化，深度融入上海生物医药产业发展生态，以本土企业的责任与担当，为上海打造全球生物医药重大战略产业高地贡献更多力量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224172615a7195246&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224172615a7195246&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2610039647","title":"銀諾醫藥-B02月10日主力淨流入318.7萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2610039647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610039647?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 16:15","pubTimestamp":1770711328,"startTime":"0","endTime":"0","summary":"02月10日, 银诺医药-B股价涨1.69%，报收27.70元，成交金额1446.5万元，换手率0.12%，振幅5.51%，量比0.37。银诺医药-B今日主力资金净流入318.7万元，上一交易日主力净流出90.0万元。该股近5个交易日下跌1.91%，主力资金累计净流入402.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出3312.5万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161707a492a4a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161707a492a4a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2610647055","title":"國產寵物減肥降糖藥進入臨床試驗，給狗和貓注射GLP-1藥物靠譜嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647055","media":"张江发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610647055?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 14:56","pubTimestamp":1770706590,"startTime":"0","endTime":"0","summary":"有必要给狗和猫注射GLP-1药物吗？与胰岛素药物相比，GLP-1药物的一大优势是体内半衰期长，给药频次低，通常是每周一次。由于在人体内的平均半衰期长达204小时，它是全球首款可两周一次给药的GLP-1产品。这款国产创新药对宠物的降糖和减重效果，将在农业农村部批准的新兽药临床试验中得到验证。给宠物注射的有效剂量和频次，在临床试验后确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210151255a6e952c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210151255a6e952c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2609563048","title":"銀諾醫藥-B(02591)：楊東妍獲委任為聯席公司秘書","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563048","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609563048?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 16:41","pubTimestamp":1770367311,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，金今女士因个人发展原因辞任公司联席公司秘书，自2026年2月6日起生效。杨东妍女士已获委任为联席公司秘书，自2026年2月6日起生效。杨女士将与另一名现任联席公司秘书施雪玲女士共同履行公司秘书职务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":112,"code":"91000000","status":"200"}]}}